Healthcare news and intelligence for Southern Africa
Daily reporting for the pharmaceutical, medical scheme and hospital sectors, published by Health Matters since 1994.
8 October 2026
Cancer in South Africa is rising, with deaths forecast to nearly double by 2050. Learn what ageing, smoking and urbanisation mean for care.
Latest
8 October 2026
8 October 2026
6 October 2026
6 October 2026
5 October 2026
More news
12 June 2026
The Lenacapavir PrEP Rollout offers six-month HIV protection, but aid cuts and clinic access gaps raise concerns for high-risk groups.
12 June 2026
Employer health insurance costs may rise in 2027 as US firms shift higher premiums, deductibles and drug expenses onto staff.
12 June 2026
Find out how DHMS AI prompts drive better health outcomes for Discovery Health Medical Scheme members through personalised guidance.
12 June 2026
The Bonitas tender dispute raises governance concerns as Medscheme challenges tenders, trustee links and member migration problems.
11 June 2026
South Africa must address critical child stunting risks to meet its 2030 health targets, as experts warn of municipal service failures.
11 June 2026
Uncover the potential of mRNA vaccines that show promise for personalized cancer treatments that target tumor cells effectively.
11 June 2026
Learn how reliance on imported medicines threatens South Africa's jobs and the industry's pharmaceutical security.
11 June 2026
Malaria cases surge despite efforts to eliminate the disease. Discover the impact of weather conditions on this worrying trend.
10 June 2026
The lenacapavir HIV Prevention Injection rollout begins in SA, but activists warn that limited supply from Gilead could blunt the impact.
9 June 2026
Daraxonrasib Pancreatic Cancer Pill nearly doubled survival in metastatic PDAC, beating second-line chemo with fewer discontinuations.
9 June 2026
Medical scheme financial pressure intensifies as healthcare costs, an ageing population, and a R11.64bn operating deficit squeeze the sector.
9 June 2026
The excessive Dialysis Product Pricing case targets Adcock Ingram, with a possible 10% turnover penalty and wider renal care cost impacts.
The archive
Browse every Health Matters article by month.